Back

An elite broadly neutralizing antibody protects SARS-CoV-2 Omicron variant challenge

Zhou, B.; Zhou, R.; Chan, J. F.-W.; Luo, M.; Peng, Q.; Yuan, S.; Mok, B. W.-Y.; Chen, B.; Wang, P.; Poon, V. K.-M.; Chu, H.; Chan, C. C.-S.; Tsang, J. O.-L.; Chan, C. C.-Y.; Au, K.-K.; Man, H.-O.; Lu, L.; To, K. K.-W.; Chen, H.; Yuen, K.-Y.; Chen, Z.

2022-01-05 immunology
10.1101/2022.01.05.475037 bioRxiv
Show abstract

The strikingly high transmissibility and antibody evasion of SARS-CoV-2 Omicron variant have posted great challenges on the efficacy of current vaccines and antibody immunotherapy.Here, we screened 34 BNT162b2-vaccinees and cloned a public broadly neutralizing antibody (bNAb) ZCB11 from an elite vaccinee. ZCB11 neutralized all authentic SARS-CoV-2 variants of concern (VOCs), including Omicron and OmicronR346K with potent IC50 concentrations of 36.8 and 11.7 ng/mL, respectively. Functional analysis demonstrated that ZCB11 targeted viral receptor-binding domain (RBD) and competed strongly with ZB8, a known RBD-specific class II NAb. Pseudovirus-based mapping of 57 naturally occurred single mutations or deletions revealed that only S371L resulted in 11-fold neutralization resistance, but this phenotype was not observed in the Omicron variant. Furthermore,prophylactic ZCB11 administration protected lung infection against both the circulating pandemic Delta and Omicron variants in golden Syrian hamsters. These results demonstrated that vaccine-induced ZCB11 is a promising bNAb for immunotherapy against pandemic SARS-CoV-2 VOCs.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 10%
18.1%
Similar papers in this journal
2
Cell Reports
○ 1498 papers in training set
Top 3%
7.7%
Similar papers in this journal
3
Nature
○ 645 papers in training set
Top 3%
6.1%
Similar papers in this journal
4
Cell Discovery
○ 57 papers in training set
Top 0.1%
5.4%
Similar papers in this journal
5
Communications Biology
○ 993 papers in training set
Top 3%
4.2%
Similar papers in this journal
6
Frontiers in Immunology
○ 638 papers in training set
Top 3%
4.2%
7
Science Advances
● 1243 papers in training set
Top 9%
3.9%
8
eLife
● 5828 papers in training set
Top 31%
3.9%
50% of probability mass above
9
iScience
○ 1154 papers in training set
Top 5%
3.9%
10
eBioMedicine
○ 183 papers in training set
Top 1%
3.2%
11
Cell Reports Medicine
○ 153 papers in training set
Top 1%
3.1%
12
PLOS Pathogens
● 820 papers in training set
Top 4%
3.1%
13
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 20%
2.6%
14
Scientific Reports
○ 3612 papers in training set
Top 47%
2.1%
15
Cell Research
○ 51 papers in training set
Top 0.6%
1.7%
16
mAbs
○ 32 papers in training set
Top 0.3%
1.5%
17
Signal Transduction and Targeted Therapy
○ 30 papers in training set
Top 0.4%
1.1%
18
Science Immunology
● 88 papers in training set
Top 2%
1.1%
19
Nature Microbiology
○ 155 papers in training set
Top 3%
1.1%
20
Molecular Therapy
○ 81 papers in training set
Top 1%
1.1%
21
Cell
○ 431 papers in training set
Top 8%
1.1%
22
Cell Host & Microbe
126 papers in training set
Top 2%
1.0%
23
Emerging Microbes & Infections
○ 74 papers in training set
Top 1%
1.0%
24
Immunity
○ 67 papers in training set
Top 2%
0.8%
25
ACS Infectious Diseases
● 82 papers in training set
Top 2%
0.8%
26
Nature Medicine
○ 125 papers in training set
Top 4%
0.8%
27
Nature Immunology
○ 79 papers in training set
Top 2%
0.8%
28
EMBO Molecular Medicine
○ 95 papers in training set
Top 4%
0.6%
29
npj Vaccines
○ 67 papers in training set
Top 1.0%
0.6%
30
PNAS Nexus
◐ 159 papers in training set
Top 5%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.